These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25525119)

  • 1. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
    Valent P; Hadzijusufovic E; Schernthaner GH; Wolf D; Rea D; le Coutre P
    Blood; 2015 Feb; 125(6):901-6. PubMed ID: 25525119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.
    Valent P; Hadzijusufovic E; Hoermann G; Füreder W; Schernthaner GH; Sperr WR; Kirchmair R; Wolf D
    Leuk Res; 2017 Aug; 59():47-54. PubMed ID: 28549238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
    Miyazaki S
    Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.
    Chen MT; Huang ST; Lin CW; Ko BS; Chen WJ; Huang HH; Hsiao FY
    Oncologist; 2021 Nov; 26(11):974-982. PubMed ID: 34418220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
    Barber MC; Mauro MJ; Moslehi J
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):110-114. PubMed ID: 29222244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
    Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
    Carneiro BA; Kaplan JB; Giles FJ
    Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
    Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
    J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
    Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
    Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Takaku T
    Rinsho Ketsueki; 2020; 61(9):1018-1027. PubMed ID: 33162495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
    Minson AG; Cummins K; Fox L; Costello B; Yeung D; Cleary R; Forsyth C; Tatarczuch M; Burbury K; Motorna O; Shortt J; Fleming S; McQuillan A; Schwarer A; Harrup R; Holmes A; Ratnasingam S; Chan KL; Hsu WH; Ashraf A; Putt F; Grigg A
    Blood Adv; 2019 Apr; 3(7):1084-1091. PubMed ID: 30944100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
    Antoszewska-Smith J; Pawlowska E; Blasiak J
    Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.